The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Infection-mimicking materials to program dendritic cells in situ
Open accessAbstract
Cancer vaccines typically depend on cumbersome and expensive manipulation of cells in the laboratory, and subsequent cell transplantation leads to poor lymph node homing and limited efficacy. We propose that materials mimicking key aspects of bacterial infection may instead be used to directly control immune cell trafficking and activation in the body. It is demonstrated that polymers can be designed to first release a cytokine to recruit and house host dendritic cells (DCs), and subsequently present cancer antigens and danger signals to activate the resident DCs and dramatically enhance their homing to lymph nodes. Specific and protective anti-tumor immunity was generated with these materials, as 90% survival was achieved in animals that otherwise die from cancer within 25 days. These materials show promise as cancer vaccines, and more broadly suggest that polymers may be designed to program and control the trafficking of a variety of cell types in the body.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dendritic cells and the control of immunity
Banchereau, J., & Steinman, R. M. (1998) · Nature · doi:10.1038/32588 · Cited by 14,336
Dranoff, G., Jaffee, E., Lazenby, A., Golumbek, P., Levitsky, H., Brose, K., Jackson, V, Hamada, H., Pardoll, D., & Mulligan, R. C. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3539 · Cited by 2,818
Self-citationMellman, I., & Steinman, R. M. (2001) · Cell · doi:10.1016/s0092-8674(01)00449-4 · Cited by 2,237
Taking dendritic cells into medicine
Steinman, R. M., & Banchereau, J. (2007) · Nature · doi:10.1038/nature06175 · Cited by 2,127
Polymeric system for dual growth factor delivery
Richardson, T. P., Peters, M. C., Ennett, A. B., & Mooney, D. J. (2001) · Nature Biotechnology · doi:10.1038/nbt1101-1029 · Cited by 1,752
Self-citationDendritic-cell control of pathogen-driven T-cell polarization
Kapsenberg, M. L. (2003) · Nature Reviews Immunology · doi:10.1038/nri1246 · Cited by 1,437
Dieu, M.-C., Vanbervliet, B., Vicari, A., Bridon, J.-M., Oldham, E., Aït-Yahia, S., Brière, F., Zlotnik, A., Lebecque, S., & Caux, C. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.2.373 · Cited by 1,425
Immunotherapeutic uses of CpG oligodeoxynucleotides
Klinman, D. M. (2004) · Nature Reviews Immunology · doi:10.1038/nri1329 · Cited by 1,012
Overwijk, W. W., Theoret, M. R., Finkelstein, S. E., Surman, D. R., de Jong, L. A., Vyth-Dreese, F. A., Dellemijn, T. A., Antony, P. A., Spiess, P. J., Palmer, D. C., et al. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030590 · Cited by 925
Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists
Kanzler, H., Barrat, F. J., Hessel, E. M., & Coffman, R. L. (2007) · Nature Medicine · doi:10.1038/nm1589 · Cited by 869
Controlled Delivery Systems for Proteins Based on Poly(Lactic/Glycolic Acid) Microspheres
Cohen, S., Yoshioka, T., Lucarelli, M., Hwang, L. H., & Langer, R. (1991) · Pharmaceutical Research · doi:10.1023/a:1015841715384 · Cited by 843
Open pore biodegradable matrices formed with gas foaming
Harris, L. D., Kim, B.-S., & Mooney, D. J. (1998) · Journal of Biomedical Materials Research · doi:10.1002/(sici)1097-4636(19981205)42:3<396::aid-jbm7>3.0.co;2-e · Cited by 824
Self-citationPeptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity.
Celluzzi, C. M., Mayordomo, J. I., Storkus, W. J., Lotze, M. T., & Falo, L. D. (1996) · The Journal of experimental medicine · doi:10.1084/jem.183.1.283 · Cited by 717
The use of dendritic cells in cancer immunotherapy
Schuler, G., Schuler-Thurner, B., & Steinman, R. M. (2003) · Current Opinion in Immunology · doi:10.1016/s0952-7915(03)00015-3 · Cited by 631
Sozzani, S., Allavena, P., D’Amico, G., Luini, W., Bianchi, G., Kataura, M., Imai, T., Yoshie, O., Bonecchi, R., & Mantovani, A. (1998) · PubMed · Cited by 605
Biological behavior of malignant melanoma cells correlated to their survival in vivo.
Fidler, I. J. (1975) · PubMed · Cited by 599
Gilboa, E. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31205 · Cited by 588
Bioabsorbable polymer scaffolds for tissue engineering capable of sustained growth factor delivery
Sheridan, M. H., Shea, L. D., Peters, M. C., & Mooney, D. J. (2000) · Journal of Controlled Release · doi:10.1016/s0168-3659(99)00138-8 · Cited by 528
Self-citationSozzani, S., Allavena, P., D’Amico, G., Luini, W., Bianchi, G., Kataura, M., Imai, T., Yoshie, O., Bonecchi, R., & Mantovani, A. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.3.1083 · Cited by 507
Migration of Dendritic Cell Subsets and their Precursors
Randolph, G. J., Ochando, J., & Partida-Sánchez, S. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090254 · Cited by 466
Development of TLR9 agonists for cancer therapy
Krieg, A. M. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31414 · Cited by 429
Emerging Design Principles in Biomaterials and Scaffolds for Tissue Engineering
GRIFFITH, L. G. (2002) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2002.tb03056.x · Cited by 372
EBI1/CCR7 Is a New Member of Dendritic Cell Chemokine Receptor That Is Up-Regulated upon Maturation
Yanagihara, S., Komura, E., Nagafune, J., Watarai, H., & Yamaguchi, Y. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.6.3096 · Cited by 369
Vitiligo in Patients with Melanoma: Normal Tissue Antigens Can Be Targets for Cancer Immunotherapy
Rosenberg, S. A., & White, D. E. (1996) · Journal of Immunotherapy · doi:10.1097/00002371-199601000-00009 · Cited by 333
Sequential chemoimmunotherapy in the treatment of metastatic melanoma.
Richards, J. M., Mehta, N., Ramming, K., & Skosey, P. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.8.1338 · Cited by 257
Kleindienst, P., & Brocker, T. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.6.2817 · Cited by 161
Jenne, L., Arrighi, J.-F., Jonuleit, H., Saurat, J. ‐., & Hauser, C. (2000) · PubMed · Cited by 159
Okamoto, T., Fujii, S., Huang, S. K. S., Hoon, D. S. �., Irie, R. F., Nizze, A. J., & Morton, D. L. (1998) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.1998.00411.x · Cited by 130
Thomas, W. R., Edwards, A. J., Watkins, M. C., & Asherson, G. L. (1980) · PubMed · Cited by 53
Okano, F., Mérad, M., Furumoto, K., & Engleman, E. G. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.5.2645 · Cited by 46
Recombinant DNA research: proposed actions under guidelines.
Health, U. N. I. O. (1984) · PubMed · Cited by 35
Implanon: A New Contraceptive Implant
Fischer, M. A. (2008) · Journal of Obstetric, Gynecologic & Neonatal Nursing · doi:10.1111/j.1552-6909.2008.00247.x · Cited by 29
Cited by
Delivery technologies for cancer immunotherapy
Riley, R. S., June, C. H., Langer, R., & Mitchell, M. J. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0006-z · Cited by 2,607
Harnessing traction-mediated manipulation of the cell/matrix interface to control stem-cell fate
Huebsch, N., Arany, P. R., Mao, A. S., Shvartsman, D., Ali, O. A., Bencherif, S. A., Rivera-Feliciano, J., & Mooney, D. J. (2010) · Nature Materials · doi:10.1038/nmat2732 · Cited by 1,569
Self-citationLee, K., Silva, E. A., & Mooney, D. J. (2011) · Journal of The Royal Society Interface · doi:10.1098/rsif.2010.0223 · Cited by 1,386
Self-citationTranslational Applications of Hydrogels
Correa, S., Grosskopf, A. K., Lopez Hernandez, H., Chan, D., Yu, A. C., Stapleton, L. M., & Appel, E. A. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c01177 · Cited by 1,143
Self-Healing Injectable Hydrogels for Tissue Regeneration
Bertsch, P., Diba, M., Mooney, D. J., & Leeuwenburgh, S. C. G. (2023) · Chemical Reviews · doi:10.1021/acs.chemrev.2c00179 · Cited by 892
Self-citation
Metadata
- Authors
- Ali, O. A., Huebsch, N., Cao, L., Dranoff, G., & Mooney, D. J.
- Venue
- Nature Materials
- Published
- 2009-01-11
- Volume
- 8
- Issue
- 2
- Pages
- 151-158
- ISSN
- 1476-1122 (ISSN-L)
- 1476-4660
- OpenAlex
- W1971416592
- Cited by
- 434
- References
- 32
- FWCI
- 6.49
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.